Becton puts $25 million into TriPath in cancer test deal
This article was originally published in Clinica
Executive Summary
TriPath Imaging has come to the attention of a major company for the second time as it forms an agreement to develop and commercialise cancer tests for Becton Dickinson. Becton will invest $25 million into the cancer screening company in exchange for 2.5 million shares. Less than a year ago, Roche Holdings invested $43 million in TriPath. Shares in TriPath leapt 37% to $8.30 on news of the latest deal.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.